md anderson logo

Houston, Texas - MD Anderson’s Gastrointestinal Center gives exemplary, customized carcinoid tumor care every step of the way. As one of the nation’s largest cancer centers, MD Anderson sees more patients with this complex type of cancer than most others, which translates into more successful outcomes for carcinoid tumors.

As one of the world’s largest cancer research centers, MD Anderson is leading the investigation into new methods of carcinoid tumor diagnosis and treatment. For instance, their researchers are studying carcinoid tumors on a molecular basis to try to find a cause.

Their status as a premier research center means they can offer clinical trials (research studies) of new treatments for carcinoid tumors. MD Anderson researchers have led the development of novel treatment strategies, including targeting of mTOR (a protein) and angiogenesis (growth of new blood vessels) in neuroendocrine tumors (including carcinoid tumors). MD Anderson researchers were involved from proof-of-concept single institution phase II to multi-national phase III studies.

MD Anderson has led the way in using chemoembolization and hepatic artery infusion to deliver chemotherapy directly to liver cancer for more effective treatment with fewer side effects.

They strive to increase survival rates for pancreatic cancer by developing novel treatment approaches. MD Anderson research paved the way for using chemotherapy to shrink pancreatic tumors prior to surgery, providing for a better chance of complete removal.

Their treatment expertise and advanced diagnostic tools allows them to deliver the most comprehensive care for GI cancers. 

Learn more about MD Anderson Cancer Center Gastrointestinal Cancer Center.

Learn more about the multidisciplinary team of medical professionals at the MD Anderson Cancer Center Gastrointestinal Cancer Center.